CRISPR/Cas9 editing of the genome for cancer modeling
CRISPR/Cas9 editing of the genome for cancer modeling
复制标题
DOI：
10.1016/j.ymeth.2017.03.007
复制
发表时间：
2017-05-15
期刊：
影响因子：
4.8
通讯作者：
Grumolato, Luca
中科院分区：
文献类型：
--
作者：
Guernet, Alexis;Grumolato, Luca
CRISPR/Cas9革命使包括癌症研究在内的许多生物学领域的基因组编辑实现了民主化。癌症是由突变的多步积累引起的，这些突变赋予转化的细胞某些恶性表型的典型生物学标志。癌症研究的主要目标之一是描述这些突变并评估它们在致癌过程中的意义。通过CRISPR/Cas9技术，在患者肿瘤中发现的遗传畸变现在可以很容易地在实验模型中重现，然后可以用于基础研究或更多的转化应用。在这里，我们回顾了不同的CRISPR/Cas9策略，这些策略已被用于在体外和体内系统中重现致癌突变，包括模拟肿瘤演变和遗传异质性的新策略。(C)2017爱思唯尔公司All rights reserved.
The CRISPR/Cas9 revolution has democratized access to genome editing in many biological fields, including cancer research. Cancer results from the multistep accumulation of mutations that confer to the transformed cells certain biological hallmarks typical of the malignant phenotype. One of the major goals in cancer research is to characterize such mutations and assess their implication in the oncogenic process. Through CRISPR/Cas9 technology, genetic aberrations identified in a patient's tumor can now be easily recreated in experimental models, which can then be used for basic research or for more translational applications. Here we review the different CRISPR/Cas9 strategies that have been implemented to recapitulate oncogenic mutations in both in vitro and in vivo systems, including novel strategies to model tumor evolution and genetic heterogeneity. (C) 2017 Elsevier Inc. All rights reserved.